CoTherix Will Position Ventavis As Complement To Oral Pulmonary Arterial Hypertension Therapies

Iloprost will launch in the second quarter 2005. CoTherix views the inhaled therapy as filling the “substantial therapeutic gap” between oral agents like Tracleer and injectable drugs such as Remodulin.